Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial-Reference-Cited by-同舟云学术

Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial

Published:2021-07 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Wong Deborah J.,Bauer Todd M.,Gordon Michael S.^ORCID,Bene-Tchaleu Fabiola,Zhu Jing,Zhang Xiaosong,Cha Edward^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. Immune surveillance of tumors;Swann;J Clin Invest,2007

3. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion;Blank;Cancer Immunol Immunother,2007

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology;Frontiers in Cardiovascular Medicine;2024-01-23

2. Neurotoxicity Associated with Immunotherapy for Lung Cancer in Clinical Trials: A Systematic Review and Meta-Analysis;2024

3. Application of organoids in precision immunotherapy of lung cancer (Review);Oncology Letters;2023-09-26

4. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors;Frontiers in Immunology;2023-03-06

5. New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC;Cancers;2022-10-27